IASP

Police forces across England plan to respond to fewer mental health calls -- here's why

Retrieved on: 
Tuesday, June 20, 2023

The Metropolitan Police Commissioner Mark Rowley has announced that the London police force is to attend fewer mental health emergencies.

Key Points: 
  • The Metropolitan Police Commissioner Mark Rowley has announced that the London police force is to attend fewer mental health emergencies.
  • As part of an approach called Right Care, Right Person, police officers will only respond to 999 mental health calls when there is an “immediate threat to life”.
  • For many years now there have been calls, from people both within the police and those experiencing mental health crises, for the police to have less of a role in mental health emergencies.
  • Under Section 136 of the Mental Health Act, police officers can detain someone if they believe that person’s mental health is causing an immediate risk to the person or others.

Emergency response

    • And in 2021/22, Mind noted that the equivalent of the population of a British town was picked up by the police in this way.
    • Yearly numbers of Section 136 detentions in England and Wales from 2017/18 to 2021/22: Scotland’s reform was prompted by similar rising numbers.
    • In 2019 four in every five 999 calls to Police Scotland were reportedly not about crime but vulnerability.

A traumatic experience

    • Police cells were never the right place for someone experiencing a mental health crisis.
    • This is as humiliating for the people being escorted as it is demoralising for the officers involved.
    • The idea behind Right Care, Right Person is that people in crisis be cared for by mental health professionals.
    • Since 2013, mental health nurses have joined police officers in street triage schemes, accompanying them on patrol to provide immediate mental health support to people.
    • Being frequently detained by the police – without proper, long-term mental health support – makes vulnerable people feel worse.
    • In the US – call the National Suicide Prevention Lifeline at 1-800-273-TALK (8255) or IMAlive at 1-800-784-2433.

Flexera Launches Flexera One Select for IBM

Retrieved on: 
Tuesday, June 6, 2023

Flexera One Select for IBM is an approved alternative to the IBM License Metric Tool (ILMT) and integrates with IBM License Service to track IBM Cloud Pak consumption.

Key Points: 
  • Flexera One Select for IBM is an approved alternative to the IBM License Metric Tool (ILMT) and integrates with IBM License Service to track IBM Cloud Pak consumption.
  • “With Flexera One Select for IBM, we give industry-leading insights into IBM software consumption to help streamline and optimize license reporting, at a time when frequently changing customer environments can be quite costly for enterprises.”
    Flexera One Select for IBM offers features including:
    Definitive technology resource data: Flexera One Select for IBM offers clear visibility and insight into IBM software consumption.
  • IBM software reporting: Flexera One Select for IBM is a modern, SaaS-based platform that, once implemented, automatically reports on peak and current consumption of IBM software.
  • Flexera One Select for IBM enables customers to report an effective license consumption of IBM products that have been purchased and deployed.

Algiax Pharmaceuticals Announces Positive Interim Analysis of Phase 2a Study with Lead Candidate AP-325 in Chronic Neuropathic Pain

Retrieved on: 
Tuesday, May 30, 2023

Algiax Pharmaceuticals , today provided an update on its ongoing Phase 2a study ( NCT04429919 ) with lead candidate AP-325 in patients with chronic neuropathic pain.

Key Points: 
  • Algiax Pharmaceuticals , today provided an update on its ongoing Phase 2a study ( NCT04429919 ) with lead candidate AP-325 in patients with chronic neuropathic pain.
  • The study is continuing as planned with topline efficacy readouts and a more in-depth safety analysis expected at the conclusion in 2024.
  • Neuropathic pain is a chronic condition that is oftentimes associated with an imbalance in excitatory and inhibitory neuronal signals.
  • In its preclinical evaluation, Aligax’s lead candidate demonstrated dose-dependent, long-lasting efficacy on mechanical and thermal pain reception in models of central neuropathic pain, peripheral neuropathic pain, and diabetic neuropathy.

Research Describes Novel Laboratory Automation Platform for Preclinical Detection and Quantification of Behavior

Retrieved on: 
Wednesday, March 8, 2023

BOSTON and DALLAS, March 8, 2023 /PRNewswire/ -- Researchers at Boston Children's Hospital and Harvard Medical School's Department of Neurobiology have developed a new approach to measure dynamic changes in behavior in an unbiased, observer-independent manner, according to a new study published in and featured on the cover of PAIN, the journal of the International Association for the Study of Pain (IASP). The investigators noted that this technology platform has the ability to characterize a broad range of physiological and pathological phenomena and can be applied to objectively and automatically characterize behaviors including such tactile hyperalgesia, sedation, and other neurological readouts.

Key Points: 
  • Results suggest new technology enables improved, high-volume characterization and quantification of in vivo behavior.
  • Principal Investigator, Clifford Woolf, Mb, BCh, PhD, Professor of Neurobiology at Harvard Medical School and Director of the F.M.
  • Kirby Neurobiology Center at Boston Children's Hospital
    This peer-reviewed study demonstrated the efficacy of a novel automated technology platform in recording freely behaving mice over time for continuous data acquisition.
  • In addition, researchers utilized a proprietary machine learning software for automatic extraction and quantification of behavior characters, allowing for objective, sensitive, and high-throughput measurement of the behavioral state of rodents.

Acute Pain Market to Observe Growth at a CAGR of 8.3% During the Study Period (2019-2032), Assesses DelveInsight

Retrieved on: 
Thursday, January 26, 2023

LAS VEGAS, Jan. 26, 2023 /PRNewswire/ -- DelveInsight's Acute Pain Market Insights report includes a comprehensive understanding of current treatment practices, acute pain emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

Key Points: 
  • As per DelveInsight analysis, the acute pain market size in the US was approximately USD 3 billion in 2021.
  • According to the assessment done by DelveInsight, the estimated total acute pain cases in the US was approximately 100 million in 2021.
  • As per the DelveInsight estimates, in the US, in 2021, diagnosed incident cases of acute pain were approximately 94 million.
  • The acute pain market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

Acute Pain Market to Observe Growth at a CAGR of 8.3% During the Study Period (2019-2032), Assesses DelveInsight

Retrieved on: 
Thursday, January 26, 2023

LAS VEGAS, Jan. 26, 2023 /PRNewswire/ -- DelveInsight's Acute Pain Market Insights report includes a comprehensive understanding of current treatment practices, acute pain emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

Key Points: 
  • As per DelveInsight analysis, the acute pain market size in the US was approximately USD 3 billion in 2021.
  • According to the assessment done by DelveInsight, the estimated total acute pain cases in the US was approximately 100 million in 2021.
  • As per the DelveInsight estimates, in the US, in 2021, diagnosed incident cases of acute pain were approximately 94 million.
  • The acute pain market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

Virpax Pharmaceuticals to Utilize Dr. Neil K. Singla to Assist in Development of Probudur™

Retrieved on: 
Wednesday, January 18, 2023

Probudur’s proprietary formulation is intended for immediate onset and has demonstrated sustained pain control for up to 96 hours in animal studies.

Key Points: 
  • Probudur’s proprietary formulation is intended for immediate onset and has demonstrated sustained pain control for up to 96 hours in animal studies.
  • Dr. Neil Singla is board certified in Anesthesiology and the Founder and Chief Scientific Officer of Lotus Clinical Research, a leading analgesic clinical research organization (CRO) with extensive analgesic and pain-related expertise.
  • Dr. Singla has published extensively and is a frequent lecturer for physicians, pharmaceutical companies, and medical research institutes throughout the country.
  • “Virpax is actively moving its programs forward in anticipation of filing Investigational New Drug applications (INDs) and beginning human clinical trials.

EQS-News: Diok RealEstate AG: ESPG (European Science Park Group) creates specialised space for innovative industries

Retrieved on: 
Wednesday, September 28, 2022

ESPG AG European Science Park Group is one of the first German real estate companies to specialise in the ownership, management and acquisition of science parks.

Key Points: 
  • ESPG AG European Science Park Group is one of the first German real estate companies to specialise in the ownership, management and acquisition of science parks.
  • This also creates synergies among the companies located within the same science park, which promotes the establishment and expansion of networks.
  • The European Science Park Group (ESPG) is a real estate company specialising in science parks.
  • The sites are usually located outside the metropolises, in areas that are considered science clusters or have a high concentration of innovative companies.

DarioHealth Publishes New Clinical Research Linking the Use of its Biofeedback Device to Reduced Back Pain

Retrieved on: 
Thursday, September 22, 2022

 NEW YORK, Sept. 22, 2022 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leader in the global digital therapeutics (DTx) market, announced today new research examining the link between the use of Dario's biofeedback device to help users improve their posture and reduced back pain at the International Association of the Study of Pain (IASP) 2022 World Congress on Pain, being held in person in Toronto, Ontario from September 19th – 23rd and virtually.

Key Points: 
  • The new research examined the connection between users of Dario's posture trainer, posture awareness and the impact on levels of pain.
  • Over the course of time, this trains users, helping them to develop awareness and adoption of proper posture.
  • "Dario's posture trainer is proven to help users reduce back pain, and with this new research we now better understand the connection between device, training and results.
  • "Dario's approach to research involves both testing the efficacy of solutions as well as seeking to understand the mediators of clinical improvement.

Lexicon Pharmaceuticals Highlights Scientific and Medical Presentations Relating to Its Successful Phase 2 Proof-Of-Concept Study of LX9211 in Painful Diabetic Neuropathy

Retrieved on: 
Tuesday, September 20, 2022

THE WOODLANDS, Texas, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced a series of scientific and medical presentations describing the progression of its investigational drug LX9211 from discovery to translation in a clinical proof-of-concept study.

Key Points: 
  • We are excited to present these findings to the medical and scientific community and expect to communicate additional LX9211 clinical and preclinical data as they become available.
  • RELIEF-DPN-1 was a Phase 2 randomized, double-blind, placebo-controlled, parallel-group, multicenter study evaluating the efficacy, safety and pharmacokinetics of LX9211 in the treatment of painful diabetic neuropathy, also referred to as diabetic peripheral neuropathic pain.
  • The RELIEF-DPN-1 study was the first of two Phase 2 proof-of-concept studies evaluating LX9211 in neuropathic pain.
  • LX9211 has received Fast Track designation from the U.S. Food and Drug Administration for the development in diabetic peripheral neuropathic pain.